1. Which of the following hematopoietic growth factor biosimilars has the same indication(s) as the reference product?

2. A common myth about biosimilars is that they won't help patients, only institutions. Which of the following statements is the best statement to bust this myth?

3. Which of the following is NOT a challenge for all hematopoietic growth factor biosimilars?

« Return to Activity